Blog

Biomind Labs Announces Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Sep 21 • 2 min read

Biomind Labs Inc. (NEO: BMND | OTC: BMNDF | FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce the completion of dose administration of 30 healthy subjects in…

Cybin Achieves Research and Development Milestones Ahead of Projected Timelines

Sep 21 • 3 min read

Cybin Inc. (NEO:CYBN | NYSE AMERICAN:CYBN), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, announced that it has successfully achieved its research and development milestones that helped to build and progress its innovative pipeline of investigational psychedelic therapeutics ahead of projected timelines. These milestones were set forth in the acquisition agreement of Adelia Therapeutics Inc….

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit

Sep 21 • 2 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at Jefferies Innovation in Mental Health Summit at 8:30am ET on 22 September 2022. A live audio webcast of the fireside chat will be accessible…

HAVN Life Provides Corporate Update

Sep 20 • 1 min read

HAVN Life Sciences Inc. (CSE: HAVN | OTC: HAVLF | FSE: 5NP) announces that the board of directors of the Company, on the advice of the Company’s Chief Financial Officer, has determined that the Company is no longer a going concern as it is unable to meet its financial obligations as they come due. A restructuring plan…

Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer ScD, Joins Its Scientific Advisory Board

Sep 20 • 2 min read

Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced the appointment of Robert S. Langer ScD, MIT David H. Koch Institute Professor and Co-founder of Moderna, to its Scientific Advisory Board. “We are excited to have Dr. Langer join our Scientific Advisory Board…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538